Revvity establishes In Vivo Imaging Center of Excellence in North Carolina

Facility designed to advance the next generation of imaging systems

Roche, Alnylam to initiate Phase 3 cardiovascular outcomes trial of zilebesiran

Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives

Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity

Replicate will receive research funding and could potentially receive up to approximately US$550 million

AbbVie to acquire Gilgamesh Pharmaceuticals’ bretisilocin for $1.2 billion

Lighthouse receives $49.2 million NIA grant to advance phase 2 study of Alzheimer’s disease

LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis

Gland Pharma receives FDA approval for Vasopressin in 5% Dextrose RTU Injection

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VASOSTRICT Injection 40 Units per 100 mL and 20 Units per 100 mL of PH Health Limited

Remedium Lifecare charts 4X growth strategy

The first pillar is advanced manufacturing, focused on upgrading existing CDMO

India releases first-ever National Guidelines/SOPs for animal blood transfusion and blood banks

Guidelines aim to establish state-regulated veterinary blood banks

Parexel appoints Jim Anthony as CCO and President, Parexel Biotech

Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role

FDA grants ODD to Keros KER-065 for treatment of Duchenne muscular dystrophy

KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB